United Health Products (UHP) (OTC: UEEC) today announced that it had completed a safety and efficacy animal study for its HemoStyp hydrocolloid product, for which it filed a patent application in August 2019. The hemostatic hydrocolloid product is formed into a gel, foam or spray in order to control bleeding and oozing from a variety of wounds. If the patent is granted and FDA approval is obtained, HemoStyp could then be bundled as a suite of multiple products for surgical and wound care applications. UHP is also working on two other complementary HemoStyp-based products that could potentially be added to its surgical product suite.
The study, A Safety and Efficacy HemoStyp Hydrocolloid Test, was done by creating bilateral femoral arteriovenous fistulas in swine. HemoStyp thrombin hydrocolloid was applied to the anastomosis suture line on one side for the cessation of bleeding, while the market leading competitive product was applied to the anastomosis suture line on the opposite side for the cessation of bleeding. Time to cessation:
Animal 1: HemoStyp Hydrocolloid Product 35 Seconds; Competitive Product 1 Min 25 Seconds
Animal 2: HemoStyp Hydrocolloid Product 35 Seconds; Competitive Product 1 Min 55 Seconds
Animal 3: HemoStyp Hydrocolloid Product 25 Seconds; Competitive Product 2 Min 20 Seconds
After the completed hemostatic test, an autopsy with pathologic evaluation was performed three weeks following the procedures and showed no difference in scarring and inflammation between the two hemostatic agents. Pathology was completed by Thomas J. Baldwin, DVM, PhD, DACVP Director, Utah Veterinary Diagnostic Laboratory, an affiliate of Utah State University, on November 22, 2019.
The study indicated that the safety properties are equivalent to a previously approved Class III competitive product. These findings will be used to create an application for an additional format to the HemoStyp family of products and an additional Class III approved product.
About United Health Products
United Health Products develops technology, manufactures and markets patented hemostatic products for the healthcare and wound care sectors. The product, HemoStyp, is derived from oxidized regenerated cellulose. HemoStyp is an all-natural product designed to control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191206005473/en/
Contacts:
United Health Products, Inc.
877-358-3444
